

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 50618

Title: Oncogenic AMAM metallopeptidase domain 28 induces gemcitabine resistance and predicts poor prognosis in pancreatic cancer

Reviewer's code: 05079464

Reviewer's country: Mexico

Science editor: Jia-Ping Yan

Reviewer accepted review: 2019-07-30 17:20

Reviewer performed review: 2019-08-05 17:33

Review time: 6 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The discussion made by the authors provides important information about new therapies against to pancreatic cancer, they discuss in appropriately form their results. However, they do not compare their results with other studies in pancreatic cancer cells



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

and other Disintegrin Metalloproteases. I recommend to the authors to review the interaction of the metalloproteases family with other malignant tumors and their therapies. Furthermore, as possible, review the metalloproteases and their interaction in treatment with pancreatic cancer cells, in order to compare the results with other studies. The authors showed the English certificate of the manuscript. However, they send the main text without the suggested corrections by the experts in the language. Thus, I recommend to review this point. The authors presented correct research methods and they provided the approval number of ethics for the study in animals, but they did not presented the ARRIVE guidelines

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 50618

Title: Oncogenic AMAM metallopeptidase domain 28 induces gemcitabine resistance and predicts poor prognosis in pancreatic cancer

Reviewer's code: 03004570

Reviewer's country: Turkey

Science editor: Jia-Ping Yan

Reviewer accepted review: 2019-08-05 09:56

Reviewer performed review: 2019-08-09 10:50

Review time: 4 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This manuscript is a comprehensive basic study that is focused on gemcitabine (GEM) resistance. Authors found that ADAM28 is involved in the GEM resistance and should be a novel target to overcome this resistance. This finding may be clinically important in



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https:// www.wjgnet.com

the future. Materials and methods are adequate. Results are clear. Figures are excellent. There are some small typing errors. First in the line 11 and line 24 of pp#18; the word "expression" is duplicated and one of them should be deleted, and then the word "reveled" should be "revealed". Secondly, in the line 6 of pp#14, correct sentence should be continued such as "... cancer therapy, in SW1990 cells...". Similarly, in the line 14 of pp#15, correct sentence should be continued as "...molecules, the correlation between...". I recommend this article for publication after these minor corrections.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☒ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☒ No

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 50618

Title: Oncogenic AMAM metallopeptidase domain 28 induces gemcitabine resistance and predicts poor prognosis in pancreatic cancer

Reviewer's code: 02734287

Reviewer's country: Croatia

Science editor: Jia-Ping Yan

Reviewer accepted review: 2019-08-06 12:13

Reviewer performed review: 2019-08-11 09:11

Review time: 4 Days and 20 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input checked="" type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input checked="" type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Genetic analysis of drug resistant pancreatic cancer is an area of great interest and the results of the study are promising. However, the language of the manuscript is very poor and the paper needs to be completely rewritten in order for the authors to be able

to convey their messages and conclusions.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No